A blue background with circles and lines in the center.
A view of the town from above.

About Us: Advancing Wound Care with Hydrivyn™ Topical Gel

At BIOHEAL THERAPEUTICS, we are focused on supporting healthcare professionals in managing chronic wounds, burns, and post-surgical sites. Our flagship product, Hydrivyn™ Topical Gel, is an amnion-derived hydrogel wound covering designed to address the practical challenges of traditional wound dressings. Developed for ease of use, conformability, and workflow support, Hydrivyn™ helps maintain a moist wound environment to support the body’s natural healing process.

Note: Hydrivyn™ Topical Gel is currently under development and has not yet received FDA clearance. It is not approved for sale or clinical use in the United States.

Driving Innovation in Wound Management

Through an exclusive global license with the Wake Forest Institute for Regenerative Medicine (WFIRM), we are advancing amnion-based technologies with the goal of broad clinical utility. Our mission is to deliver wound care solutions that:

✅ Help maintain a moist wound environment for a variety of wound types
✅ Support management of chronic wounds, burns, and post-surgical sites
✅ Offer convenient application for frontline healthcare providers

Our Vision for Wound Care Solutions

We are developing a pipeline of wound care technologies designed to:

✔️ Enhance workflow efficiency and ease of application
✔️ Provide shelf-stable, user-friendly formats for clinical environments
✔️ Support scalable use across wound care and dermatology settings

Our goal is to deliver science-based, clinician-centered products that align with the evolving needs of today’s healthcare system.

Built by Medtech Experts

Founded by Bruce Anderson and Steve Anderson, BIOHEAL THERAPEUTICS draws on more than 70 years of combined experience in medical device development and human tissue applications. Our team has contributed to the successful commercialization of cardiovascular, orthopedic, and surgical adhesive technologies that have helped shape modern patient care.

Our Commitment

Headquartered in Greater Atlanta, Georgia, BIOHEAL THERAPEUTICS is dedicated to advancing wound care with practical, impactful solutions that support both patients and healthcare providers.

We’re building the next chapter in wound management with products designed for ease of use, cost-effectiveness, and adaptability to today’s clinical environments.

 

Meet the Team

Bruce Anderson

President & CEO

Bruce Anderson is a category-defining innovator in regenerative medicine and surgical hydrogel technologies, with over 25 years of experience turning breakthrough science into commercial success. As cofounder and CEO of BIOHEAL THERAPEUTICS, founded in 2017, Anderson is leading the development of BioHeal Hydrogel XG-100, a novel, biologically active hydrogel designed for chronic wounds, burns, and topical post surgical procedures. By combining solubilized porcine amnion and hyaluronic acid, BIOHEAL is establishing advanced topical regenerative therapies.

Anderson's journey as a hydrogel pioneer began with BioGlue, the world's first FDA-approved protein-based surgical adhesive, cleared in 1999 under Humanitarian Device Exemption for use in the repair of acute thoracic aortic dissection. He played a key role in its clinical positioning and commercial success, helping to create a new standard in cardiovascular surgery and opening the door to a global market for surgical sealants.

Throughout his career, Anderson has contributed to the development and commercialization of more than 20 implantable human cardiovascular and orthopedic tissues and multiple Class II and III medical devices-consistently redefining what's possible in tissue-based and regenerative technologies.

In 2008, he was elected Vice President of US Sales and Global Marketing for Artivion (formerly CryoLife, Inc.), where he led a team of over 120 professionals across global product marketing. From 2002 to 2007, he served as Director of US Sales, driving double-digit growth in the company's portfolio during a critical phase of expansion.

Mr. Anderson holds a degree from the University of South Florida at Tampa.

Steve Anderson (1939-2023): A Legacy of Innovation in Medical Devices

Steve Anderson was the Chairman of the Board and co-founder of BIOHEAL THERAPEUTICS, LLC, serving from its founding 2017 until his passing in 2023. A visionary entrepreneur and industry pioneer, he dedicated his career to advancing life-saving medical technologies.

Mr. Anderson was also the co-founder, President, CEO of CryoLife, Inc. (now Artivion) from 1984 - 2015. Under his leadership, the company went public on Nasdaq in 1994 and transitioned to the New York Stock Exchange in 1997.

Before founding CryoLife, he held key executive roles in the medical device industry:

A Legacy of Impact

CryoLife's cardiac tissues revolutionized pediatric reconstructive surgery, helping to save the lives of thousands of children, while its vascular tissues preserved the limbs of thousands of adults suffering from peripheral vascular disease. CryoLife’s products have reached 80 countries, and its cryopreserved human tissues and surgical adhesives have improved the lives of nearly 2 million people worldwide.

A true entrepreneur, pioneer, and leader in the medical device industry, Mr. Anderson’s contributions transformed cardiovascular surgery and tissue transplantation.

He was a graduate of the University of Minnesota at Minneapolis.